Timothy L. MacDonald
Fundador en SphynKx Therapeutics LLC .
Perfil
Timothy L.
MacDonald was the founder of Cavion, Inc. (founded in 2005) where he held the title of Vice President-Drug Discovery from 2005 to 2013.
He is also the founder of SphynKx Therapeutics LLC (founded in 2010) where he holds the title of Vice President-Drug Discovery.
Dr. MacDonald's current job is as a Professor at the University of Virginia.
Dr. MacDonald's former jobs include Director at Adenosine Therapeutics LLC and Advisor at Limulus Management Co. LLC.
Dr. MacDonald received a doctorate degree from The Trustees of Columbia University in The City of New York in 1975 and an undergraduate degree from the University of California, Los Angeles in 1971.
Dr. MacDonald is also the founder of Catena Pharmaceuticals, Inc.
Cargos activos de Timothy L. MacDonald
Empresas | Cargo | Inicio |
---|---|---|
SphynKx Therapeutics LLC
SphynKx Therapeutics LLC Pharmaceuticals: MajorHealth Technology SphynKx Therapeutics LLC engages in developing, discovering and commercializing novel therapies for the treatment of fibrosis. Its Sphingosine 1-phosphate (S1P) is recognized as a key regulator of many of the cellular processes that promote wound healing and fibrogenesis, which include fibroblast and immune cell migration, vascular leak, proliferation, angiogenesis, and TGF-ß signaling. The company was founded by Andrew Bolt, Kevin R. Lynch, Webster Santos and Timothy L. Macdonald in 2010 and is headquartered in Charlottesville, VA. | Fundador | 01/01/2010 |
University of Virginia | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Timothy L. MacDonald.
Empresas | Cargo | Fin |
---|---|---|
Catena Pharmaceuticals, Inc.
Catena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Catena Pharmaceuticals, Inc. is focused on the development and commercialization of novel GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's proprietary chemistry is uniquely capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states. Catena focuses its research and product development efforts around manipulation of the biology of the blood-borne signaling molecule lysophosphatidic acid (LPA). Its products will either block the signaling of LPA, or reduce production of LPA, or mimic LPA. The company was founded by Kevin Lynch and Tim MacDonald in the year 2008 and is headquartered in Durham, NC. | Fundador | 09/07/2013 |
Limulus Management Co. LLC
Limulus Management Co. LLC Investment ManagersFinance Limulus Management Co. LLC is a venture capital firm founded by Lawrence Miller and Paul Howard in 1999. It is headquartered in Newton, Massachusetts. | Corporate Officer/Principal | - |
Cavion, Inc.
Cavion, Inc. Pharmaceuticals: MajorHealth Technology Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA. | Fundador | - |
Adenosine Therapeutics LLC
Adenosine Therapeutics LLC Pharmaceuticals: MajorHealth Technology Adenosine Therapeutics LLC manufactures and develops pharmaceutical products. It provides drugs for sepsis, heart attack, vascular injury, asthma, spinal cord injury and organ transplantation. The company was founded by Joel M. Linden, George A. Beller and Robert S. Capon in 1999 and is headquartered in Charlottesville, VA. | Director/Miembro de la Junta | - |
Formación de Timothy L. MacDonald.
The Trustees of Columbia University in The City of New York | Doctorate Degree |
University of California, Los Angeles | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 5 |
---|---|
Adenosine Therapeutics LLC
Adenosine Therapeutics LLC Pharmaceuticals: MajorHealth Technology Adenosine Therapeutics LLC manufactures and develops pharmaceutical products. It provides drugs for sepsis, heart attack, vascular injury, asthma, spinal cord injury and organ transplantation. The company was founded by Joel M. Linden, George A. Beller and Robert S. Capon in 1999 and is headquartered in Charlottesville, VA. | Health Technology |
Cavion, Inc.
Cavion, Inc. Pharmaceuticals: MajorHealth Technology Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA. | Health Technology |
Limulus Management Co. LLC
Limulus Management Co. LLC Investment ManagersFinance Limulus Management Co. LLC is a venture capital firm founded by Lawrence Miller and Paul Howard in 1999. It is headquartered in Newton, Massachusetts. | Finance |
Catena Pharmaceuticals, Inc.
Catena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Catena Pharmaceuticals, Inc. is focused on the development and commercialization of novel GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's proprietary chemistry is uniquely capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states. Catena focuses its research and product development efforts around manipulation of the biology of the blood-borne signaling molecule lysophosphatidic acid (LPA). Its products will either block the signaling of LPA, or reduce production of LPA, or mimic LPA. The company was founded by Kevin Lynch and Tim MacDonald in the year 2008 and is headquartered in Durham, NC. | Health Technology |
SphynKx Therapeutics LLC
SphynKx Therapeutics LLC Pharmaceuticals: MajorHealth Technology SphynKx Therapeutics LLC engages in developing, discovering and commercializing novel therapies for the treatment of fibrosis. Its Sphingosine 1-phosphate (S1P) is recognized as a key regulator of many of the cellular processes that promote wound healing and fibrogenesis, which include fibroblast and immune cell migration, vascular leak, proliferation, angiogenesis, and TGF-ß signaling. The company was founded by Andrew Bolt, Kevin R. Lynch, Webster Santos and Timothy L. Macdonald in 2010 and is headquartered in Charlottesville, VA. | Health Technology |
- Bolsa de valores
- Insiders
- Timothy L. MacDonald